title: ICL670A: preclinical profile.
authors.affiliation: Novartis Pharma AG, 4002 Basel, Switzerland.
authors.forename: Hanspeter
authors.initials: H
authors.lastname: Nick
authors.forename: Agnes
authors.initials: A
authors.lastname: Wong
authors.forename: Pierre
authors.initials: P
authors.lastname: Acklin
authors.forename: Bernard
authors.initials: B
authors.lastname: Faller
authors.forename: Yi
authors.initials: Y
authors.lastname: Jin
authors.forename: René
authors.initials: R
authors.lastname: Lattmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Sergejew
authors.forename: Suzanne
authors.initials: S
authors.lastname: Hauffe
authors.forename: Helmut
authors.initials: H
authors.lastname: Thomas
authors.forename: Hans Peter
authors.initials: HP
authors.lastname: Schnebli
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D002144:Callithrix; D000077588:Deferasirox; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism; D015394:Molecular Structure; D051381:Rats; D014230:Triazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D017086:beta-Thalassemia / Q000188:drug therapy
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D007501:Iron; D000077588:Deferasirox